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Abstract
Background—Gene expression patterns have not been extensively examined in the context of 
clinical features of eosinophilic esophagitis (EoE).
Aims—To assess whether gene expression is associated with clinically defined phenotypes in 
adults with EoE.
Methods—This was an analysis of prospectively collected esophageal biopsies in newly 
diagnosed EoE patients. We determined differential gene expression with a 94 gene panel in 
relation to clinical features and phenotypes. These included: endoscopic findings of esophageal 
rings, stricture, narrowing, linear furrows, exudates, edema, and dilation; an allergic phenotype; an 
inflammatory phenotype, and a fibrostenotic phenotype.
Results—In 89 EoE cases analyzed, patients with exudates on endoscopy had multiple 
differences in gene expression compared to patients without exudates, though patients with 
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exudates also had higher eosinophil counts (172 vs 106 eos/hpf; p=0.01). Genes associated with 
esophageal narrowing included CCL26 (q-value=0.028), ALOX15 (q=0.011), GRK5 (q=0.029), 
CPA3 (q=0.012), and TRIM2 (q=0.0027). TRIM2 was also associated with the fibrostenotic 
phenotype (q=0.0051). No genes were associated with the inflammatory or atopic phenotypes, or 
with dilation.
Conclusions—Multiple genes are associated with exudates, possibly related to higher 
eosinophil counts. However, a number of genes, including those related to both inflammation and 
remodelling, are associated with esophageal narrowing. In particular, TRIM2 is associated with 
clinical fibrotic phenotypes.
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Introduction
Eosinophilic esophagitis is a Th2-mediated allergen/immune-mediated esophageal disorder.
[1, 2] Since its description in the mid-1990s, there has been rapid understanding of EoE 
pathogenesis. In particular, the genetic underpinnings of EoE are beginning to be elucidated.
[3] Landmark work by Blanchard, Rothenberg, and colleagues described a set of genes, 
termed the “EoE transcriptome”, that are differentially expressed in EoE patients compared 
to those with gastroesophageal reflux disease (GERD) and normal controls.[4, 5] Recent 
work has identified a subset of genes that are highly discriminatory for diagnosis of EoE 
compared to non-EoE controls,[6] and this same gene set also appears to be responsive, 
normalizing after successful treatment.[7] In addition, a series of genome-wide association 
studies (GWAS) have identified several single nucleotide polymorphisms (SNP) that are 
highly associated with EoE,[8–10] and may increase EoE risk.[11]
In addition to genetics, there has been recognition of different clinical phenotypes in EoE.
[12–15] Perhaps the most important one categorizes patients into either an inflammatory-
predominant appearance in the esophagus (endoscopic findings of edema, exudates, and 
linear furrows) or a fibrostenotic-predominant appearance (esophageal strictures or 
narrowing).[12, 16] Other phenotypes can include atopic vs non-atopic, male vs female, 
white vs non-white, adult vs pediatric, treatment responders vs non-responders, and 
connective tissue disease-associated.[14, 17] However, associations between genetics and 
phenotypes have not been extensively examined in EoE. Initial investigations have shown a 
SNP in transforming growth factor beta-1 (TGF-β1) may be associated with treatment 
response,[18] that gene expression related to mast cells correlated with dysphagia measured 
by a pediatric symptom score,[19] and that expression of some genes may be associated with 
steroid response.[20]
Because there have been no studies specifically assessing the relationship between genotype 
and clinical phenotype, the aim of this study was to assess whether gene expression is 
associated with clinically defined phenotypes in adults with EoE. We hypothesized that 
expression of genes related to epithelial integrity and remodelling would be associated with 
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a fibrostenotic phenotype, while expression of genes related to Th2 cytokines would be 
associated with an atopic phenotype.
Materials and Methods
Study design, patients, and clinical data collection
We conducted an analysis of biopsy samples and data collected during a prospective cohort 
study of EoE. The parent study, details of which have been described previously,[21–24] 
enrolled adults (≥ 18 years) undergoing upper endoscopy at University of North Carolina for 
symptoms of dysphagia, heartburn, refractory reflux, or other upper gastrointestinal 
symptoms. They were excluded if they had a known (prevalent) diagnosis of EoE or 
eosinophilic gastroenteritis, acute GI bleeding, active anticoagulation, known esophageal 
cancer, prior esophageal surgery, known esophageal varices, or medical instability or 
multiple comorbidities precluding enrollment in the clinical opinion of the endoscopist. 
Informed consent, including consent for future use of stored biopsy specimens, was obtained 
prior to the endoscopy. This study was approved by the UNC Institutional Review Board.
Only incident cases of EoE, with baseline (pre-steroid or dietary treatment) samples and data 
available, were included in the present study. EoE was diagnosed as per 2011 consensus 
guidelines.[1] Specifically, cases were had at least one symptom of esophageal dysfunction, 
≥15 eos/hpf on esophageal biopsy after an 8-week proton pump inhibitor trial (20–40 mg 
twice daily of any of the available agents, prescribed at the discretion of the clinician), and 
exclusion of other causes of esophageal eosinophilia. Of note, subjects with proton pump 
inhibitor-responsive esophageal eosinophilia (PPI-REE) were excluded from the present 
analysis because we did not have sufficient pre-PPI treatment banked samples available to 
conduct the analysis, and it has previously been shown that gene expression profiles in this 
subgroup normalize after PPI administration,[25] so post-PPI samples would not be 
appropriate to address to the study question.
Demographics, clinical, and endoscopic data were recorded prospectively using standardized 
case report forms. During the endoscopy, research protocol esophageal biopsies were 
obtained (two from the proximal, one from the middle, and two from the distal esophagus) 
in order to determine tissue eosinophil counts and ensure EoE diagnostic sensitivity.[26, 27] 
We also collected research-protocol gastric and duodenal biopsies to exclude concomitant 
eosinophilic gastroenteritis. After masking the slides as to clinical status, peak esophageal 
eosinophil counts were determined based on our previously validated methodology.[28, 29]
Sample collection, RNA extraction, and gene expression
In addition to the biopsies that were obtained for histologic analysis, additional esophageal 
biopsy samples were collected, labeled with a de-identified study number, masked as to 
clinical status, and stored at −80 °C RNA-later (Life Technologies/Thermo-Fisher Scientific, 
Grand Island, NY) for future use. Samples remained frozen until study enrollment was 
complete and we were ready to perform the present analysis. At that time, we retrieved a 
single RNA-later-preserved biopsy from the mid-esophagus (10 cm above the 
gastroesophageal junction) for gene expression determination. The rationale for using a 
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single mid-esophageal biopsy was based on our prior work showing that gene expression in 
EoE was similar throughout the esophagus.[30]
Gene expression testing was performed at Miraca Life Sciences (Phoenix, AZ) as previously 
described.[7] After thawing and tissue homogenization, RNA was extracted using the 
RNeasy Mini Extraction Kit (Qiagen, Valencia, CA) per the manufacturer’s instructions. 
The concentration was measured using spectrophotometry (NanoDrop, Wilmington, DE) 
with 16.5 ng/µl of RNA for a total of 500 ng considered acceptable. cDNA synthesis was 
carried out using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) with PCR 
performed on ABI 9700 (Applied Biosystems, Foster City, CA). The cDNA and TaqMan 
Universal Master Mix II, no UNG (Life Technologies) were loaded onto custom Taqman 
TLDA cards containing preloaded Taqman gene expression assays in a 384-well format. 
This consisted of the 94 gene panel that was previously developed for EoE and 2 
housekeeping genes (GAPDH and 18S). PCR was performed on Quant Studio 7 (Life 
Technologies) to determine the gene expression levels measured as threshold cycles (Ct). 
Samples with a GAPDH value of <30 Ct were considered acceptable. A gene expression 
summary score was calculated using a previously established algorithm.[6] Specifically, the 
Ct value of the housekeeping gene was subtracted from the Ct value of each gene of interest 
to acquire the ΔCT, and then the absolute values of the normalized gene Ct values were 
summed for each gene in the gene expression panel. In general, a gene score below 333 is 
characteristic of EoE, with lower scores being more reflective of a diagnosis of EoE.[6]
Clinical phenotype definition and statistical analysis
Clinical findings and phenotypes for analysis were defined as follows. Endoscopic findings 
of interest were reported by the endoscopic and included: esophageal rings, stricture, 
narrowing, furrows, exudates, and edema, as well as whether esophageal dilation was 
performed. Strictures were defined as the presence of a focal area of constriction in the 
esophagus. Narrowing was defined as an area where the lumen had a smaller caliber, but was 
more diffuse than what would be expected for a focal stricture. The fibrostenotic phenotype 
was defined as the presence of stricture, narrowing, or dilation, regardless of other 
endoscopic findings. A “severe” fibrotic phenotype was defined if there was a focal stricture 
or narrowing with an esophageal diameter measured as ≤10mm (such that a standard adult 
upper endoscope used in our procedures unit would not pass). The inflammatory phenotype 
was defined as the presence of exudates, edema, or furrows, in the absence of dilation being 
performed, and regardless of other endoscopic findings. An inflammatory “only” phenotype 
was defined as having exudates, edema, or furrows without other endoscopic findings. The 
allergic phenotype was defined as the presence of any atopic condition.
We used summary statistics to describe the clinical features of the EoE cases. Among the 
EoE cases, the mean summary gene score was compared for the patients with and without 
each endoscopic finding or phenotype using a two-sample t-test. We then determined 
differential gene expression for each endoscopic finding or phenotype using the Mann-
Whitney U test with a false discovery rate, calculated using the Benjamini-Hochberg 
procedure, of 0.1. Differential gene expression was then plotted on a heat map. Finally, we 
performed unsupervised consensus clustering with the R package, ConsensusClusterPlus 
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(parameters maxK=6, reps=50, pItem = 0.8) using all of the genes.[31] 
ConsensusClusterPlus provides stable clusters by iteratively clustering a random subset of 
samples a given amount of times and then using the consensus results. This yielded two 
distinct clusters. We then compared clinical, endoscopic, and histologic features between 
each of these clusters, to determine the clinical phenotypic correlates of the gene expression 
clustering.
Results
Patient characteristics and phenotypes
A total of 89 incident cases of EoE were included in this analysis. Full clinical details for 
this population have been previously described.[7] In brief, the mean age was 37 ± 13 years, 
58% were men, 94% were white, and nearly all (99%) had dysphagia-predominant 
symptoms. 74% had at least one atopic condition (29% asthma, 65% allergic rhinitis/
sinusitis, 8% eczema, 38% food allergies) and were categorized into the allergic phenotype.
On endoscopy, typical EoE findings were common, including 80% with rings, 25% with a 
focal stricture, 36% with narrowing, 87% with furrows, 47% with exudates, and 56% with 
edema. Dilation was performed in 29 (33%). A total of 49 patients (55%) were categorized 
into the fibrostenotic phenotype, with 13 (15%) meeting criteria for “severe” fibrosis. There 
were 57 (64%) who met the definition for the inflammatory phenotype, but only 6 (7%) with 
inflammation-only findings. The average peak eosinophil count at baseline for overall study 
population was 137 ± 124 eos/hpf.
Gene expression-phenotype associations
Summary gene scores differed with the presence of several individual endoscopic findings, 
but did not differ substantially for the atopic phenotypes or endoscopically defined 
inflammatory or fibrostenotic phenotypes (Figure 1). For example, EoE patients with 
esophageal narrowing (149 vs 228; p = 0.009), linear furrows (186 vs 287; p = 0.02), 
exudates (129 vs 263: p < 0.001), or edema (171 vs 236; p = 0.03) had significantly lower 
gene scores compared to those without these findings. There was also a trend for lower 
scores in the presence of rings (187 vs 247; p = 0.10).
Differential gene expression for individual genes is shown relation to clinical phenotypes 
and endoscopic findings as a heat map in Figure 2. Patients with exudates on endoscopy had 
differences in gene expression for the majority of genes compared to patients without 
exudates, and many of these differences were at the Benjamini-Hochberg corrected q-value 
< 0.025 level. Of note, patients with exudates also had higher eosinophil counts than those 
without exudates (172 ± 141 eos/hpf vs 106 ± 99; p = 0.01). There was a trend towards 
increased expression of the gene TRIM2 with the presence of both rings and stricture (q-
values = 0.086 and 0.091, respectively). Several genes had decreased expression and were 
associated with narrowing (Figure 3A), including CCL26 (q-value = 0.028), ALOX15 (q-
value = 0.011), GRK5 (q-value = 0.029), APOBEC3A (q-value = 0.076), HPGDS (q-value = 
0.057), CPA3 (q-value = 0.012), POSTN (qvalue = 0.058), and TRIM2 (q-value = 0.0027). 
Increased expression of TRIM2 was also associated with the fibrostenotic phenotype and 
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severe fibrosis (q-value = 0.0051 and 0.027, respectively) (Figure 3B). IL4 and CFI were 
associated with furrows (q-value = 0.043 and 0.052, respectively), and there was a trend for 
an association between CRISP2 (q-value = 0.058), CRISP3 (q-value = 0.097), and 
TSPAN12 (q-value = 0.087) and edema. We did not identify any genes that were clearly 
associated with either the inflammatory or atopic phenotypes, or with esophageal dilation.
Unsupervised clustering of eosinophilic esophagitis
We performed unsupervised clustering of the EoE samples using the gene expression data, 
and identified two independent clusters (Figure 4). The principal component analysis plot 
shows segregation in PC1 (Figure 4A). The heat map of all genes in this gene expression 
panel show that the immune related genes are higher in cluster 2 and cell proliferation and 
epithelial makers are higher in cluster 1 (Figure 4B).
In terms of clinical features, cluster 1 had a higher proportion of women than cluster 2 (49% 
vs 34%), but this was not significant (p = 0.16) (Table 1). There were also no differences in 
other demographic, atopic features, or endoscopically defined phenotypes. However, there 
were a number of individual endoscopic correlates. EoE cases in cluster 1 were more likely 
to have exudates (69% vs 25%; p < 0.001), edema (67% vs 45%; p = 0.04), and crêpe-paper 
mucosa (11% vs 0%; p = 0.02). There were also histologic differences, with EoE cases in 
cluster 1 having more eosinophil degranulation (100% vs 91%; p = 0.04), eosinophilic 
microabscesses (80% vs 45%; p < 0.001), and basal layer hyperplasia (53% vs 33%; p = 
0.02), as compared to cluster 2 (Table 1).
Discussion
While knowledge about the role of genetics in the pathogenesis of EoE has rapidly 
increased,[3] there is a relative paucity of data examining clinical correlates of gene 
expression. We conducted an analysis of prospectively collected and banked esophageal 
biopsies in order to assess whether gene expression is associated with clinically defined 
phenotypes in adults with EoE, a study that is the first of its kind. Overall, we found a 
number of gene expression-clinical correlations of note. First, mean gene scores were lower, 
indicating more active EoE with more differentially expressed genes, in patients with the 
individual endoscopic findings of exudates, furrows, edema, and narrowing. Second, there 
was significant differential gene expression in multiple genes in EoE patients with exudates, 
and this could be related to substantially higher eosinophil counts in those patients. There 
were also a number of genes, including those related to both inflammation and remodelling, 
associated with esophageal narrowing. In particular, the gene TRIM2 was associated with 
clinical fibrotic phenotypes. Interestingly, gene expression was not associated with the atopic 
or inflammatory phenotypes. Finally, an unsupervised principle component analysis revealed 
that our EoE cases could be segregated into two populations based on gene expression, with 
features of one cluster including higher esophageal eosinophil counts and a larger proportion 
of exudates, edema, and crêpe-paper mucosa. We did not find specific gene expression 
patterns in patients with and without an atopic phenotype, or in those with and without an 
inflammatory phenotype.
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Our study provides new information about patients with fibrostenotic remodelling of the 
esophagus in EoE, which has previously been felt to be a consequence of unchecked 
inflammation during a long disease duration prior to diagnosis or treatment.[12, 32–35] 
These patients have also been noted to have a less compliant esophagus which raises the risk 
for food bolus impaction,[36, 37] and may constitute a population that is more refractory to 
topical steroid treatment.[17] However, the reason why some patients develop a more 
fibrotic phenotype has not been clear. Our data may provide some clues. In patients with 
esophageal narrowing, a number of genes have increased expression, including CCL26, 
ALOX15, GRK5, APOBEC3A, HPGDS, CPA3, POSTN, and TRIM2. These genes are 
involved in inflammatory processes, for example CCL26 (eotaxin-3), and ALOX15 
(arachidonate 15-lipoxygenase), as well as mast cell function (CPA; carboxypeptidase A3) 
and remodeling (POSTN; periostin).[3–5, 38] The gene TRIM2 (tripartite motif containing 2 
protein) may be of special interest, as this was also associated with rings, stricture, the 
fibrostenotic phenotype, and “severe” fibrosis. TRIM2 is an E3 ubiquitin ligase that has been 
implicated in neuronal development and function[39–41] as well as tissue homeostasis 
related to ischemia.[42] Mutations in this gene have been associated with axonal neuropathy 
and Alzheimer’s disease.[43, 44] However, the function of TRIM2 in EoE or in fibrosis has 
not been explored specifically, and this should be a future direction of mechanistic research. 
Interestingly, we did not find evidence of differential expression of desmoglein (DSG), 
which has previously been linked to dysregulation of the epithelial barrier.[45]
We also found strong trends towards associations between IL4, CFI, and furrows, and 
between CRISP2, CRISP3, and TSPAN12 and edema, but the mechanisms behind these 
associations are unknown and would need to be elucidated in future research. IL4 codes for 
interleukin 4, a key type 2 cytokine that has been implicated in EoE pathogenesis,[3] and 
recent phase 2 data support blocking the IL-4 receptor as a promising treatment strategy for 
EoE.[46] CFI codes for complement factor I, a serine protease involved in complement 
cascade regulation, but which has not been associated with atopy.[47] CRISP2 and -3 code 
for cysteine-rich secretory proteins 2 and 3 which are thought to be involved in epithelial 
processes, and TSPAN12 codes for tetraspanin-12, a regulator of cell surface signal 
transduction, but the exact role of these genes in EoE pathogenesis is not known.[3, 6]
There are some data in the literature that provide additional context for our findings. In the 
initial description of the EoE transcriptome, Blanchard and colleagues showed similar gene 
expression profiles between males and females with EoE, and allergen-sensitized and non-
sensitized EoE patients.[4] This latter finding is consistent with our finding of no differences 
in expression for the atopic phenotype. In a related study, similar expression profiles were 
also seen in EoE patients with a family history of EoE and those without a family history.
[48] Martin and colleagues showed that gene expression related to mast cells correlated with 
dysphagia as measured by a validated pediatric symptom score.[19] This included the gene 
CPA3 which we observed was linked to esophageal narrowing in the present study. In a 
recent abstract, a TSLP risk allele was associated with having multiple EoE food triggers, 
and could impact on treatment recommendations.[49] Two published studies have also 
looked at the impact of genetic variability on treatment outcomes. Aceves and colleagues 
demonstrated that children with EoE more likely to be responders treatment if they had a 
SNP (CC genotype) at the -509 position in the TGF-β1 promoter.[18] Though this finding 
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has not yet been replicated, Butz and colleagues found several differentially expressed genes 
were associated with treatment response in a sub-analysis from a randomized clinical trial of 
fluticasone.[20] Some of these, including ALOX15, CCL26, APOBEC3A, and POSTN, 
overlap with findings from our study, but we could not specifically assess treatment response 
since we were examining baseline features only. However, we have presented abstract data 
where the gene panel did not appear to predict histologic response to treatment.[50]
There are limitations of this study to acknowledge. First, this was a single center study of 
adults only, so it is difficult to compare directly to prior gene expression results that have 
been primarily in pediatric EoE populations. Second, the endoscopic findings, and in 
particular the fibrostenotic findings were determined by the performing endoscopist, so there 
may be some variability in reporting. Third, the gene expression analysis was limited to the 
94 genes in the preexisting panel, and it is possible that additional differences might be 
noted with whole genome RNA sequencing. However, a full RNA sequencing project was 
beyond the scope of the current study. Last, the study design only allows determination of 
associations, so we are unable to know if these expression differences are a result of the 
disease or a cause of the phenotype, and mechanistic analysis would be required to 
understand the role of genes such as TRIM2 in the pathogenesis of EoE. However, there are 
a number of strengths to the study that lend validity to the results. This study used specimens 
that were collected during a rigorously conducted prospective cohort study of EoE. In 
addition, all of the samples were obtained from newly diagnosed EoE cases prior to either 
topical steroid or dietary elimination treatment. Specimens were handled and stored 
uniformly, and extensive clinical data were available to allow full clinical, endoscopic, and 
histologic characterization of the EoE cases. This study is also the first of its kind to 
extensively evaluate the association between gene expression and clinical/endoscopic 
phenotypes.
In conclusion, in this study of prospectively collected samples, we found that multiple genes 
in the 94 gene EoE diagnostic panel were associated with endoscopic findings of exudates, 
possibly related to significantly higher eosinophil counts in these patients. We noted a more 
focused number of genes, including those related to both inflammation and remodelling, 
were associated with esophageal narrowing. In particular, TRIM2 was associated with 
clinical fibrotic phenotypes. These results provide initial insight into genetic determinants of 
different presentations of EoE, and provide a foundation for future mechanistic studies. The 
future studies should also focus on assessing phenotypes over time and predicting 
progression of phenotypes.
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Gene score by clinical phenotype, endoscopic findings, and endoscopic phenotypes. Black 
bars indicate the presence of a finding or phenotype. Gray bars indicate the absence of a 
finding or phenotype. Asterixes indicate a significant difference (p < 0.05) between mean 
gene scores in EoE cases where the finding/phenotype is present or absent.
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Heat map showing adjusted −log10(p-value) determined by differential expression of the 
different phenotypes by the Mann-Whitney U test. A tile is displayed if the adjusted q-value 
< 0.1 for each gene in the 94 gene panel (noted on the vertical axis), as distributed among 
clinical phenotype, endoscopic findings, and endoscopic phenotypes (noted on the horizontal 
axis). The lighter and more yellow the color, the stronger the differential gene expression 
between EoE cases with or without a finding/phenotype.
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Boxes represent median ± interquartile range and whiskers represent ± 1.5 * interquartile 
range. qRT-PCR normalized to GAPDH. (A) RNA expression differences in selected genes 
in patients where esophageal narrowing is either absent (pink) or present (blue). (B) TRIM2 
RNA expression differences by selected endoscopic findings and phenotypes, as noted on 
the y axis.
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(A) PC1 and PC2 from a principal component analysis. The color represents the clusters 
determined by ConsensusClusterPlus used on all genes in the 94 gene panel. This shows that 
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the EoE cases independently cluster into two groups (cluster 1 indicated by gray dots and 
cluster 2 as indicated by red dots) based on gene expression. (B) Heat map showing 
differential gene expression for all genes (rows) and patient samples (columns) in the study. 
Samples and genes clustered using hierarchical clustering of Euclidean distance. Decreased 
gene expression is indicated by more blue coloration and increased expression is indicated 
by more yellow coloration. The three color bars at the top of the heat map show sex (male in 
blue; female in pink), presence of exudates (present is yellow; absent is green), and cluster 
assignment (cluster 1 is gray; cluster 2 cases is red).
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Table 1







Age (mean years ± SD) 36.4 ± 11.2 38.1 ± 14.3 0.55
Male (n, %) 23 (51) 29 (66) 0.16
White (n, %) 41 (91) 43 (98) 0.18
Symptoms (n, %)
  Dysphagia 44 (98) 44 (100) 0.32
    >5 yrs (n=70) 16 (50) 24 (63) 0.27
  Heartburn 7 (15) 4 (9) 0.35
  Abdominal pain 6 (13) 1 (2) 0.05
  Nausea/vomiting 1 (2) 0 (0) 0.32
Any atopic disease (n, %) 33 (73) 33 (75) 0.98
  Asthma 17 (38) 9 (20) 0.06
  Rhinitis/sinusitis 28 (62) 30 (68) 0.65
  Dermatitis 5 (11) 2 (5) 0.24
  Food allergies 18 (40) 16 (36) 0.66
Endoscopic findings (n, %)
  Rings 37 (82) 34 (77) 0.56
  Stricture 10 (22) 12 (27) 0.58
  Narrowing 17 (38) 15 (34) 0.72
  Furrows 41 (91) 36 (82) 0.20
  Crêpe-paper mucosa 5 (11) 0 (0) 0.02
  White plaques/exudates 31 (69) 11 (25) < 0.001
  Edema/decreased vascularity 30 (67) 20 (45) 0.04
  Hiatal hernia 5 (11) 4 (9) 0.75
  Dilation performed 15 (33) 14 (32) 0.88
  Fibrostenotic 24 (53) 25 (57) 0.75
    “Severe fibrosis” 6 (13) 7 (16) 0.73
  Inflammatory 29 (64) 28 (64) 0.94
    “Inflammation only” 3 (7) 3 (7) 0.98
Eosinophil count (max eos/hpf ± SD) 117.8 ± 141.1 95.4 ± 87.6 0.001
Associated histologic findings (n, %)
  Eosinophil degranulation 45 (100) 40 (91) 0.04
  Eosinophil microabscesses 36 (80) 20 (45) < 0.001
  Basal layer hyperplasia 24 (53) 14 (33) 0.02
  Spongiosis 39 (87) 36 (82) 0.23
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